Overcoming Therapy Resistance in Colorectal Cancer: Targeting the Rac1 Signaling Pathway as a Potential Therapeutic Approach
Cells · 26.10.2024 · 13 (21) · 1776
DOI: 10.3390/cells13211776 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 26.10.2024. Verfasst von Luciano E Anselmino und 8 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Inmunología Clínica y Experimental de Rosario (IDICER, CONICET-UNR), Facultad de Ciencias Médicas (UNR), Rosario 2000, Argentina. Hauptthemen laut MEDLINE: Colorectal Neoplasms, rac1 GTP-Binding Protein, Drug Resistance, Neoplasm, Signal Transduction. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto Nacional del Cáncer, Agencia Nacional de Promoción Científica y Tecnológica, Agencia Santafesina de Ciencia, Tecnología e Innovación.
Abstract (Originalsprache)
Colorectal cancer (CRC) is the third most commonly diagnosed type of cancer worldwide and is responsible for numerous deaths. 5-fluorouracil (5-FU) is an effective chemotherapy drug commonly used in the treatment of CRC, either as monotherapy or in combination with other drugs. However, half of CRC cases are resistant to 5-FU-based therapies. To contribute to the understanding of the mechanisms underlying CRC resistance or recurrence after 5-FU-based therapies, we performed a comprehensive study integrating in silico, in vitro, and in vivo approaches. We identified differentially expressed genes and enrichment of pathways associated with recurrence after 5-FU-based therapies. Using these bioinformatics data as a starting point, we selected a group of drugs that restored 5-FU sensitivity to 5-FU resistant cells. Interestingly, treatment with the novel Rac1 inhibitor, 1A-116, reversed morphological changes associated with 5-FU resistance.. Moreover, our in vivo studies have shown that 1A-116 affected tumor growth and the development of metastasis. All our data allowed us to postulate that targeting Rac1 represents a promising avenue for the development of new treatments for patients with CRC resistant to 5-FU-based therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Inmunología Clínica y Experimental de Rosario (IDICER, CONICET-UNR), Facultad de Ciencias Médicas (UNR), Rosario 2000, Argentina.
- Instituto de Inmunología Clínica y Experimental, CONICET, Rosario 2000, Argentina.
- Centro de Investigación y Producción de Reactivos Biológicos (CIPReB), Facultad de Ciencias Médicas (UNR), Suipacha 660, Rosario 2000, Argentina.
- Centro de Investigación del Cáncer de Rosario (CIC-R), Red de Investigación del Cáncer de Rosario (RICaR), Rosario 2000, Argentina.
- Institut du Thorax, Inserm, CNRS, Université de Nantes, 44000 Nantes, France.
ORCID-Profile: Luciano E Anselmino, Florencia Malizia, Aylén Avila, Cecilia Farré, Vincent Sauzeau, Mauricio Menacho Márquez
Förderung
- Instituto Nacional del Cáncer
- Agencia Nacional de Promoción Científica y Tecnológica
- Agencia Santafesina de Ciencia, Tecnología e Innovación
- Fundación Florencio Fiorini
Zitieren
APA
Anselmino, L. E., Malizia, F., Avila, A., Cesatti Laluce, N., Mamberto, M., Zanotti, L. C., Farré, C., Sauzeau, V., & Menacho Márquez, M. (2024). Overcoming Therapy Resistance in Colorectal Cancer: Targeting the Rac1 Signaling Pathway as a Potential Therapeutic Approach. Cells, 13(21), 1776. https://doi.org/10.3390/cells13211776
Vancouver
Anselmino LE, Malizia F, Avila A, Cesatti Laluce N, Mamberto M, Zanotti LC, et al. Overcoming Therapy Resistance in Colorectal Cancer: Targeting the Rac1 Signaling Pathway as a Potential Therapeutic Approach. Cells. 2024;13(21):1776. doi:10.3390/cells13211776
BibTeX
@article{Anselmino2024,
author = {Anselmino, Luciano E and Malizia, Florencia and Avila, Aylén and Cesatti Laluce, Nahuel and Mamberto, Macarena and Zanotti, Lucía C and Farré, Cecilia and Sauzeau, Vincent and Menacho Márquez, Mauricio},
title = {Overcoming Therapy Resistance in Colorectal Cancer: Targeting the Rac1 Signaling Pathway as a Potential Therapeutic Approach},
journal = {Cells},
year = {2024},
volume = {13},
number = {21},
pages = {1776},
doi = {10.3390/cells13211776}
}
EUVIMED